H3G34W与H3K36M免疫组化在细针穿刺及粗针活检中高特异性诊断骨巨细胞瘤与软骨母细胞瘤
该研究在细针穿刺和/或粗针活检标本中验证H3G34W和H3K36M免疫组化对富巨细胞骨肿瘤的诊断价值。H3G34W在26例骨巨细胞瘤中22例阳性(85%),H3K36M在8例软骨母细胞瘤中全部阳性,两者在组织学模仿病变中均阴性。活检与手术标本免疫组化结果一致率为96%(152/158)。
要点
- H3G34W免疫组化在骨巨细胞瘤中阳性率85%(22/26),在组织学模仿病变中均阴性。
- H3K36M免疫组化在软骨母细胞瘤中全部阳性(8/8),在模仿病变中均阴性。
- 活检与手术标本免疫组化结果一致率96%(152/158),支持在有限活检中确认诊断。
核心结论
- H3G34W和H3K36M免疫组化分别对骨巨细胞瘤和软骨母细胞瘤具有高度特异性,可用于有限活检标本的诊断确认。
- 部分骨巨细胞瘤H3G34W免疫组化阴性可由替代性H3F3A突变(G34L、G34V)解释。
研究设计与样本
- 采用针对组蛋白H3.3 G34W和K36M的单克隆抗体进行免疫组化,标本来自2个机构的细针穿刺和/或粗针活检。
- 检测病例包括骨巨细胞瘤26例(含2例恶性)、Paget病相关骨巨细胞瘤1例、软骨母细胞瘤8例、动脉瘤样骨囊肿7例及骨肉瘤13例。
- 对所有4例H3G34W免疫组化阴性的骨巨细胞瘤进行了H3F3A和H3F3B Sanger测序。
主要发现
- H3G34W免疫组化在26例骨巨细胞瘤中22例阳性(85%),在所有组织学模仿病变中阴性。
- H3K36M免疫组化在8例软骨母细胞瘤中全部阳性,在所有组织学模仿病变中阴性。
- 免疫组化结果在活检与手术标本间一致率为96%(152/158)。
- 测序在1例H3G34W免疫组化阴性骨巨细胞瘤中检出H3F3A G34L突变,另1例检出G34V突变,剩余2例未发现突变。
关键数值与推荐
- H3G34W免疫组化阳性:22/26例骨巨细胞瘤(85%)。
- H3K36M免疫组化阳性:8/8例软骨母细胞瘤。
- 活检与手术标本免疫组化结果一致:152/158例(96%)。
临床怎么用
- 在细针穿刺或粗针活检的富巨细胞骨肿瘤中,可用H3G34W免疫组化支持骨巨细胞瘤诊断。
- 可用H3K36M免疫组化支持软骨母细胞瘤诊断,两者在组织学模仿病变中均阴性。
- H3G34W免疫组化阴性时,应考虑到替代性H3F3A突变(如G34L、G34V)的可能。
局限性
- 研究样本量有限,骨巨细胞瘤26例、软骨母细胞瘤8例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnosing giant cell-rich bone tumors can be challenging on limited biopsies. H3 histone family member 3A (H3F3A) (G34W/V/R/L) mutations are present in the majority of giant cell tumors (GCTs) of bone and H3 histone family member 3B (H3F3B) (K36M) mutations are present in nearly all chondroblastomas, but are absent in histologic mimics. Mutation-specific immunohistochemistry (IHC) is highly specific for GCT and chondroblastoma in surgical excisions. The objective of the current study was to validate H3G34W and H3K36M IHC in the diagnosis of giant cell-rich bone tumors on fine-needle aspiration and core needle biopsy specimens. METHODS: IHC was performed using monoclonal antibodies against histone H3.3 G34W and K36M in GCTs of bone (26 cases, including 2 malignant cases), GCT of Paget disease (1 case), chondroblastoma (8 cases), aneurysmal bone cyst (7 cases), and osteosarcoma (13 cases) with available fine-needle aspiration and/or core needle biopsy specimens from 2 institutions. H3F3A and H3F3B Sanger sequencing was performed on all 4 H3G34W IHC-negative GCTs. RESULTS: IHC for H3G34W was positive in 22 of 26 GCTs (85%) and negative in all histologic mimics. IHC for H3K36M was positive in all 8 chondroblastomas and negative in all histologic mimics. IHC results were concordant between biopsy and surgical specimens in 152 of 158 samples (96%). Sequencing identified alternate H3F3A G34L and G34V mutations in 1 IHC-negative GCT each, but no mutation was found in the remaining 2 cases. CONCLUSIONS: H3G34W and H3K36M IHC is highly specific for GCT and chondroblastoma, respectively, among giant cell-rich bone tumors, and is useful for confirming the diagnosis in limited biopsies. The presence of alternate H3F3A mutations accounts for the H3G34W IHC negativity in a subset of GCT of bone cases. Cancer Cytopathol 2018. © 2018 American Cancer Society.
引用
- Schaefer IM, Fletcher JA, Nielsen GP, et al. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Cancer Cytopathol. 2018. PMID: 29757500. doi:10.1002/cncy.22000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。